KPV 10mg

Description

Strength: 10mg
CAS: 67727-97-3
Chemical Formula: C₁₆H₃₀N₄O₄
Molecular weight: 342.43 g/mol
Peptide Sequence: Lys-Pro-Val
Synonyms: Lysine Proline Valine
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

KPV (10 mg) is a short synthetic peptide. It is derived from the C-terminal region of alpha-melanocyte–stimulating hormone (α-MSH), a peptide involved in immune and inflammatory signaling research.

KPV has been studied in laboratory models focusing on inflammatory processes, immune signaling, and epithelial tissue research. Due to its small size, it has been investigated for stability and activity in both in vitro and in vivo experimental systems.

This product is supplied as a 10 mg lyophilized powder in a sealed research vial. Shelf life is 24 months when stored under recommended conditions.

• Peptide sequence: Lys-Pro-Val
• Molecular formula: C₁₆H₃₀N₄O₄
• Molecular weight: 342.43 g/mol
• CAS number: 67727-97-3
• Purity: High research-grade purity (≥95% typical analytical standard)
• Supplied as a 10 mg lyophilized peptide in a sterile vial
• Derived from α-MSH C-terminal sequence (Lys-Pro-Val)
• Studied in inflammation and immune response research models
• For laboratory research use only

KPV is being investigated for its potential to modulate inflammatory signaling in laboratory models. As a fragment of α-MSH, it has been studied for its interactions with immune-related pathways involved in cytokine regulation.

In experimental systems, KPV has been studied for cellular uptake via the PepT1 transporter and subsequent modulation of NF-κB signaling pathways. This mechanism, in combination with its influence on cytokine regulation, differentiates KPV from other anti-inflammatory compounds.

Research applications have included:

• Inflammation-related laboratory models
• Gastrointestinal system research
• Skin and epithelial tissue investigations
• Immune signaling studies

In experimental settings, KPV has been evaluated for its effects on inflammatory mediators and markers of barrier integrity. These findings are limited to controlled research environments.

Research remains preclinical and investigational.

Published research involving KPV has primarily been conducted in preclinical models, including cell culture and animal studies.

Reported experimental dosing has included:

• Microgram to milligram per kilogram (mg/kg) ranges in animal studies
• Topical, oral, or parenteral administration depending on research design
• Short- to mid-term study durations

Observed outcomes in research contexts have included modulation of inflammatory markers and changes in tissue response indicators. These results are limited to experimental research settings and are not clinical recommendations. No approved therapeutic dosing guidelines exist.

• Store at 2–8 °C for standard handling
• For long-term storage, maintain at ≤–20 °C
• Room temperature exposure during transport is acceptable
• Protect from light
• Avoid repeated freeze–thaw cycles
• Handle using appropriate laboratory protective equipment
• Dispose of materials in accordance with institutional biosafety procedures

References

1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026
2. Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282-2284.
3. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. doi:10.1210/er.2007-0027
4. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73.

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.